Director's Report

Dr Elisabete Weiderpass, Director

Scientific Council, 61st Session (remote) 12-14 February 2025


International Agency for Research on Cancer

World Health Organization



Table of Contents							
1. Major scientific highlights by Pillar/Brai	nch	3					
 Introduction: a few updates 			1-6				
Pillar 1: data for action		6	3				
• Cancer Surveillance (CSU)			9-13				
 Pillar 2: understanding the causes Genomic Epidemiology (GEM) Nutrition and Metabolism (NME) Laboratory support, Biobanking and serventiation 	ices		14 15-17 18-22 23-24				
 Pillar 3: from understanding to prevention Environment and Lifestyle Epidemiology Epigenomics and Mechanisms (EGM) Early Detection, Prevention and Infection 	(ENV)		25 26-30 31-35 36-40				
 Pillar 4: Knowledge Mobilization Evidence Synthesis and Classification (ESC) Learning and Capacity Building (LCB) 	C)		41 42-46 47-51				
 2. Highlights from the meeting of the 66th S 3. Update from the 60th Session of the Scient 			52-67 58-82				
Director's Report - SC/61 st Session	12-14 February 2025						





The slide shows IARC organigram as of 1 November 2024. Charu Mehta was appointed Director of Administration and Finance (DAF) in October 2024.

The four pillars reflect IARC's fundamental activities:

Pillar 1: data for action

Pillar 2: understanding the causes

Pillar 3: from understanding to prevention

Pillar 4: knowledge mobilization



IARC was represented at the Seventy-seventh World Health Assembly, which took place in Geneva, Switzerland, from 27 May to 1 June 2024.


Several IARC scientists, including IARC Director Dr Elisabete Weiderpass, presented the Agency's work during different side events to the World Health Assembly, and IARC personnel met with colleagues and other parties interested in cancer prevention at the IARC stand on Monday 27 May.



IARC was well represented at the World Cancer Congress, which took place on 17–19 September 2024 in Geneva, Switzerland. More than a dozen IARC scientists presented their research on a range of topics in the field of cancer prevention.

In addition to a scientific session sponsored by IARC entitled "Cancer prevention that works: reducing cancer burden faster through multisectoral collaborations" on 18 September, IARC researchers led and participated in sessions on issues such as building resilient cancer systems, early diagnosis, cancer control in low- and middle-income countries, multi-cancer blood tests, and the cost of cancer.





The following slides present some scientific highlights for **Pillar 1**, which includes the **Cancer Surveillance (CSU) Branch**.

Global Initiative for Cancer Registry Development (GICR) - translating knowledge to action: the GICRNet




<u>CSU</u>

IARC has been working with cancer registries worldwide for close to three-quarters of a century, providing standards for the collection and reporting of cancer incidence and survival internationally. In countries undergoing social and economic transition, the IARC-led Global Initiative for Cancer Registry Development (GICR) established six IARC Regional Hubs to serve as a first point of contact for countries seeking assistance in cancer registration and following the addition of 13 IARC-GICR Collaborating Centres has delivered technical assistance, education and capacity building to complement the normative guidance from WHO in national cancer control programmes.

To provide further support, the GICRNet was created to launch a network of regional trainers selected from the IARC Hub regions that were tasked with co-producing educational material on selected topics and disseminating these through interactions with registry staff, such as courses and directed support. A critical aspect is continued engagement with trainers regularly so that there is a true network that can be called for assistance.

Two GICRNet workshops were held in November of last year focusing on developing a network of trainers worldwide. The workshops are held as a modified version of train-the-trainer, where instead of one expert training others, participants collectively develop the needed educational resources to train others in their respective regions.

The first workshop was held in collaboration with Bloomberg Philanthropies and Vital Strategies, and targeted for trainers with specific expertise in CanReg5, IARC's opensource software used by registries for collection, validation, analysis and dissemination of cancer data. Thirty-five new trainers were added to the GICRNet for CanReg5.



<u>CSU</u>

The GICR e-Learning Series, launched on World Cancer Day on 4 February, comprises 16 comprehensive training modules providing foundational knowledge and skills development in the principles and practices of cancer registration. It is aimed at anyone who is considering starting or has started a cancer registry career, from those who are newly hired to staff members wishing to refresh their knowledge – registrars, analysts, data managers, and directors.

The GICR e-Learning Series provides guidance on all aspects of cancer registry practices – an introduction to cancer surveillance, registry operations, data analysis and dissemination for cancer control impact. Each module is aligned with the international standards of cancer registration that are recommended by the International Association of Cancer Registries (IACR). Modules also correspond to training material used by the GICR.


To provide recognition for those that acquire the necessary knowledge in cancer

registration through the completion of all the modules and successfully pass a test, the designation as a Certified Global Tumor Registrar will be given together with a certificate.

The GICRNet Regional Trainers are asked to provide additional learning support as facilitators for users of the Series. Learners may wish to ask for assistance in understanding certain concepts or discuss how they can be applied in their region. To help effectively assist learners, GICRNet trainers are encouraged to become familiar with modules relevant to their expertise area.

Facilitator Guide Purpose

This guide is designed for GICR partners, particularly GICRNet Regional trainers, who are asked to support cancer registries within their regions. It is designed specifically for those designated by IARC to act as a facilitator in GICR e-Learning Series. The goal is to familiarize facilitators with standardized teaching materials and resources aimed at enhancing support for cancer registries within regions, equipping them with the tools and knowledge to effectively lead sessions and support participants in achieving their learning objectives.




<u>CSU</u>

The International Association of Cancer Registries (IACR) and IARC have been linked from the early days of cancer registration and in official relations for 50 years, since 1974. The Branch provides the permanent Executive Secretary to the IACR, the professional umbrella organisation for all population-based cancer registries worldwide. As well as facilitating the use of international standards and tools for cancer registration, the Secretariat at IARC arranges the annual IACR scientific conference for its members.

In November last year, the IACR Scientific Conference was held in Beijing, China and co-hosted by the National Cancer Center and Cancer Hospital, Chinese Academy of Medical Sciences. Over 500 participants from China and around the world met in Beijing to attend workshops, keynote and hear scientific talks from 25 countries.

A highlight was to hear of the expansive programme of cancer registry development alongside national cancer control from Prof He, Director of the National Cancer Center as well as Dr Wei, who directs the National Cancer Registry Office. The participants learned that the National Central Cancer Registry now has over 2800 cancer registries covering close to 99% of the districts and countries of China, an extraordinary achievement. As ever, it was is as much as a social as a scientific meeting, and we would like to sincerely thank our Chinese hosts for their extraordinary commitment and generous support to the IACR community in hosting the 45th meeting of the Association.




<u>CSU</u>

Even today, limited information is available as to how advances in early detection and screening have translated to population-level cancer survival benefits for countries in sub-Saharan Africa. This is an in-depth analysis of cancer survival in sub-Saharan Africa using data from 13 population-based cancer registries to evaluate survival outcomes for 18 cancers in sub-Saharan Africa, focusing on disparities in survival. The study is performed alongside capacity supports for registries and countries to allow regular, future, collection and data analysis in their own setting.

Key findings of the study showed that survival for preventable cancers like cervical and lung cancer remains alarmingly low, with fewer than half of the patients surviving three years for many cancer types. Survival varied by gender and cancer type but not consistently by country-level Human Development Index. They emphasize the urgent need to enhance **cancer prevention**, diagnosis, and care in the region, providing crucial data for policy and advocacy efforts.


Global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut consumption




<u>CSU</u>

Consuming smokeless tobacco or products containing areca nut is linked to numerous diseases including oral cancer. Previous studies have estimated the impact of consuming smokeless tobacco and areca nut on deaths but not on the impact on new cancer diagnoses which is important to monitor prevention actions. There were also lacking estimates on impact of the different types of smokeless tobacco products and areca nut consumptions. In this work IARC and collaborators provided a more complete picture of the burden of these risk factors on health care and the potential impact of primary prevention.

This work highlights the significant burden of oral cancer attributable to smokeless tobacco and areca nut consumption, accounting for nearly one in three cases globally. The analysis also showed that 90% of these cases occur in low- and middle-income countries. Specific products were responsible for up to 84% of cases in high-burden countries like India and Bangladesh. Importantly, while smokeless tobacco control progress has stalled, areca nut lacks global regulatory frameworks. The findings underscore the urgent need to strengthen control measures for both products and develop global policies for areca nut prevention.



The following slides present some scientific highlights for **Pillar 2 – understanding the causes**, that includes the **Genomic Epidemiology (GEM) Branch**, the **Nutrition and Metabolism (NME) Branch**, and the **Laboratory support**, **Biobanking and services (LSB)**.



<u>GEM</u>

Mutographs is a Cancer Grand Challenges project that aims to understand the causes of five different cancer types across five continents by generating mutational signature profiles.

Through whole-genome sequencing of 981 colorectal tumours from 11 countries with varying incidence rates, GEM identified several signatures, including colibactin signature. Colibactin signature (SBS88), resulting from *pks+ Escherichia coli* exposure, has been associated with colorectal cancer tumorigenesis.

Colibactin signature had a higher prevalence in tumors from younger patients, showing a potential role in the increasing incidence of colorectal cancer in younger individuals.

This study is under revision in Nature.

Article	Published in Natur	e* Fig 1 Kruskal-Wallis, p = 4.4e − 104
U	riation of mutagenic idney cancer genomes	
https://doi.org/10.1038/s41586-024-07368-2 Received: 4 May 2023 Accepted: 28 March 2024 Published online: 1 May 2024	Sergey Senkin ¹⁵⁸ , Sarah Moody ²⁵⁸ , Marcos Díaz-Gay ¹⁴⁵ , Behnoush Abedi-Ardel Thomas Cattiaux ¹ , Aida Ferreiro-Iglesias ¹ , Jingwei Wang ² , Stephen Fitzgerald ² , Mariya Kazachkova ^{3,58} , Raviteja Vangara ^{3,45} , Anh Phuong Le ³ , Erik N. Bergstrom Azhar Khandekar ^{3,45} , Burçak Oul ^{3,43} , Saamin Cheema ³ , Calil Latimer ³ , Emily T Joshua Ronald Atkins ⁸ , Karl Smith-Byrne ⁹ , Ricardo Cortez Cardoso Penha ¹ , Chris Priscilia Chopard ¹ , Valérie Gaborieau ¹ , Pekka Keski-Rahkonen ¹⁰ , David Jones ² , Jo	Fig 2 homas ² , 4000 time Carreira ⁹ , 5
> Key findings :	whole genomes from 11 countries	
 Thailand, rare elsewhere (F In Japan, a mutational sign elsewhere (Fig 2) A ubiquitous signature was 	$ \frac{4^{6^{17}} d^{10^{10}} d^$	
• These results indicate the e affecting 10s of millions of	Romania Canada 0.8 g Brazil Barbie Russia 0.75 g Russia 0.77 g 0.65 %	
*Senkin et al, <i>Nature</i> 2024, On bel Director's Report - SC/61 st Sessio	RESEARCH CHALL	


<u>GEM</u>

The renal cancer Mutographs study has been published in Nature.

A study of 962 renal cancer whole genomes from 11 countries has revealed three main findings:

- A DNA signature for Aristolochic acid was present in most cases from Romania, Serbia and Thailand, and largely absent elsewhere, implying widespread exposure in the region.
- In Japan, a mutational signature of unknown cause was found in more than 70% cases and absent elsewhere.
- A third mutational signature was found to predominantly occur in high incidence countries of Czech Republic and Lithuania.

These results indicate that exposure to both known or unknown potent mutagens are widespread, affecting many millions of people, and can be detected by sequencing renal tissue.




<u>GEM</u>

A new study led by GEM and published in the Journal of the American Medical Association assesses whether the incidence of late-stage cancer could be a suitable alternative end-point in randomized clinical trials of cancer screening, in place of cancer-specific mortality, the gold-standard end-point.

Based on 41 randomized clinical trials evaluating the effectiveness of screening tests, the findings suggest that the rate of late-stage cancers may be a suitable alternative metric to cancer deaths for some types of cancer but not for others.

GEM found that reductions in the rate of late-stage diagnoses for lung and ovarian cancers led to similar reductions in cancer deaths. For breast cancer, the reduction in deaths was smaller than the reduction in the incidence of late-stage cancers, and for colorectal and prostate cancers, the relationship between the two metrics was weak.




Body shape phenotypes reflecting adiposity subtypes were derived with principal components analysis using body mass index, height, weight, waist-to-hip ratio, and waist and hip circumference.

A generally obese (PC1) and a tall, centrally obese (PC3) body shape, as you can see on the left-hand side of the slide, were positively associated with CRC risk in observational analyses in UK Biobank.

In a genome-wide association study in UK Biobank, over 3,000 genetic variants were related to these body shapes. A Mendelian randomization analysis confirmed positive associations of PC1 and PC3 with colorectal cancer risk in an genetic consortium including over 52,000 colorectal cancer cases.

Brain tissue–specific genetic instruments, mapped to PC1 through enrichment analysis, was the main driver of the relationship between PC1 and CRC, while the relationship between PC3 and CRC was predominantly driven by adipose tissue–specific genetic instruments. This study suggests distinct putative causal pathways between adiposity subtypes and CRC.



A large set of proteomics data was recently measured in16 thousands samples in EPIC using the SomaLogic assay.

The NME branch led a study relating 7k protein concentrations to the risk of 24 distinct cancer sites, as well to the risk of cancer overall.

More than 16 hundreds proteins were found to be associated with at least one cancer site.

Also, a total of 53 proteins were associated with overall cancer. Specifically, we observed:

- Proteins that were associated in several site-specific analyses, like GDF15, circled in red.
- Proteins whose association did not reach statistical significance in any of the sitespecific analyses, but that showed a consistent association across the 24 cancer sites, like GPR37, circled in blue.

These results illustrate the unique and novel value of the EPIC proteomics data, which will likely lead to the identification of biological pathways involved in the carcinogenesis across several cancer sites.

Several site-specific analyses on the role of proteomics data are currently ongoing in EPIC, as well as analyses on mortality, CVD and T2D.


 Hepatic Steatosis, Liver Cancer and Mortality Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) is characterized by fat accumulation in the liver MASLD is closely linked to obesity, unhealthy lifestyle habits and the Metabolic Syndrome Associations with risk of hepatocellular carcinoma and mortality were investigated in EPIC T1: Hepatocellular carcinoma (HCC) hazard ratios (95% Cl) for MASLD 								
MASLD Index ¹				MA	SLD Index ¹			
	HCC Risk	No MASLD	MASLD		Mortality Risk ²	No MASLD	MASLD	
	Crude Model ¹	1.00	5.65 (3.11, 10.28)		All-cause	1.00	1.40 (1.26, 1.56)	
	Multivariable Model ²	1.00	6.66 (3.17, 13.98)		Cancer mortality	1.00	1.27 (1.08, 1.51)	
 Crude model conditioned on matching factors (centre, age, sex, time of the day and fasting status at blood collection, menopausal status and hormone replacement therapy) 				CVD mortality	1.00	1.60 (1.20, 2.11)		
 Multivariable model adjusted for smoking, physical activity, lifetime alcohol pattern, education level and alcohol intake at recruitment. MASLD estimated by application of the fatty liver index and based on EASL criteria. Model stratified by centre, sex, and age; adjusted for smoking, physical activity, lifetime alcohol pattern, education level, HbA1c, fasting status and Mediterranean diet score. 								
Director's Report - SC/61 st Session 12–14 February 2025 Mayen AL et al. BMC Med 2024 20								

Hepatic steatosis, or fat accumulation in the liver, is linked to unhealthy diets and lifestyles, contributing to metabolic dysfunction. The extent of its association with risk of mortality or liver cancer development is unclear. In a study within the EPIC cohort, metabolic dysfunction-associated steatotic liver disease (MASLD) was estimated via the Fatty Liver Index and following criteria established by the European Association for the Study of the Liver.

In Table 1, on the left, findings published in BMC Medicine, display strong associations between MASLD and the risk of hepatocellular carcinoma using data from a case-control study nested within EPIC.

Table 2, on the right, shows that MASLD is strongly associated with increased risks of all-cause, cancer, and cardiovascular mortality.

These studies provide additional evidence on the importance of improving individuals' metabolic health for preventing hepatocellular carcinoma, as well as all-cause and cause-specific mortality



Inflammation and immune function are suspected to play a major role in cancer development and progression, and may offer an important biological pathway in the relationship between excess adiposity and some female cancers.

We conducted a series of studies nested within EPIC and other cohorts to investigate this interplay. In a first study on about 600 case-control pairs from EPIC, on the left-hand side of slide, InterLeukin-6 was associated with a 18% increased risk of endometrial cancer and this association was confirmed in Mendelian Randomization analyses. IL-6 mediated 24% of the association between obesity and endometrial cancer before menopause and 5% after menopause. In a second study, we observed that pre-diagnostic IL-6 levels were associated with a higher all-cause and breast cancer specific mortality among breast cancer patients after adjusting for tumour characteristics and lifestyle factors, including body-mass-index.

In a third study, to the right hand-side of the slide, principal components reflecting body shapes were differentially associated to IL-6. These results suggest that inflammatory process related to cancer outcomes could be specific to the distribution of adiposity in human bodies.

	oesophagea	l ader					neck cancer and een UPF and these cancers?		
		N	Mediation by Waist-Hip ratio	HR	(95% CI)	P-value			
	Head and neck cancer	910	Total effect	1.23	(1.12, 1.33)	<0.001	Table 1. UPF (per 10% g/d increase)		
			Direct effect, HR	1.22	(1.11, 1.32)	<0.001	and the risk of head & neck cance and oesophageal adenocarcinoma		
			Proportion mediated	5 %	(2.70, 10.3)	-	and proportion mediated by WHR.		
	Oesophageal Adeno	215	Total effect	1.20	(1.02, 1.36)	0.03			
			Direct effect, HR	1.17	(0.99, 1.33)	0.06	Manufac Daminia at al 500.2024		
	Carcinoma		Proportion mediated	15 %	(7.63, 72.3)	-	Morales-Berstein et al. EJN 2024		
 WHR accounts for <15% of the UPF and these cancers Other mechanisms may be involved, e.g. food additives, contaminants present in UPF Director's Report - SC/61st Session 12-14 February 2025 22 									

The consumption of Ultra Processed Food (UPF) has been associated with several cancer sites, including head & neck cancer and oesophageal adenocarcinoma.


In an EPIC study led by scientists in the NME branch, we investigated whether the associations between consumption of UPF and the risk of head and neck cancer and oesophageal adenocarcinoma was mediated by adiposity, specifically participants' waist-to-hip ratio measured at baseline. As one can see, the results in the Table show that mediation analyses suggested that Waist Hip ratio explained a modest proportion of the relationship between UPF and the risk of Head and Neck and Oesophageal carcinoma.

This study indicated that other mechanisms, in addition to the obesogenic effects of UPF, are expected to be involved in these relationship, including food additives and contaminants present in UPF. Associations between UPF and these cancers might be partially driven also by residual confounding from smoking habits and socio-economic position.



<u>LSB</u>


- Biobanks concentrate significant volumes of physical samples <u>and</u> of associated data. Increasingly the data volumes surpass those of physical samples.
- There is limited understanding of current regulatory frameworks in LMICs in relation to healthcare data for research and data kept in biobanks.
- There is limited understanding on how digital technologies impact the LMICs medical research, biobanking and the wider medical services ecosystem.
- A series of publications and a book were produced in 2024, often with the collaboration of BCNet members from LMICs, summarising the current understanding of the digital aspects of biobanking and medical research.



<u>LSB</u>

Organoid technology has developed rapidly in the last few years. Organoids are a 3D cellular model in vitro, which can simulate the characteristics of parental organs in terms of tissue structure, cell function, and genomic profile.

Organoids have been widely used in biomedical research, especially in cancer research. However, there are challenges when it comes to biobanking organoids, such that they retain the characteristics of the original tissue in the long-term. Several collaborations are ongoing to address these biobanking challenges. The current publications focused on gastric cancer, as it is a difficult cancer to study and treat and presents numerous challenges in relation to reliable organoid generation.



The following slides present some scientific highlights for **Pillar 3 – from understanding to prevention**, that includes the **Environment and Lifestyle Epidemiology (ENV) Branch**, the **Epigenomics and Mechanisms (EGM) Branch**, and the **Early Detection**, **Prevention and Infections (EPR) Branch**.

	Cancer Care Terminology in African Languages								
	Unique survey led by an IARC postdoctoral fellow Dr Simba from Zimbabwe								
• • • •	 107 responses, 32 countries, 44 African language "Cancer" translations classified as: phonetic or borrowed terms (32%) e.g. 'saratani' from Arabic unknown term (28%) neutral connotation (22%) negative connotations (18%) – e.g. of fear, tragedy, incurability, and fatal 	Cancer Kokolo Gomarara Jejere Khansa							
•	• "Radiotherapy" had the highest percentage of negative connotations (22%]), e.g. describing treatment as burning with fire, heat, or electricity.								
•	• Highlights attention needed to guide and develop cancer communication free from fear, stigma or blame.								
Simba et al. JAMA Network Open 2024									
	Director's Report - SC/61 st Session 1	2–14 February 2025	26						


ENV Branch

The Environment and Lifestyle Epidemiology (ENV) Branch conducts a wide range of fieldwork epidemiology studies in low- and middle-income countries, including in African countries.

Coupled with this, they have a strong capacity building element. The present work exemplifies a unique undertaking of one of these African postdocs, Dr Hannah Simba, who herself came to IARC via the IARC Fellowship program.

Clinicians has expressed to ENV scientists concerning the challenges of communicating a cancer diagnosis and treatment to patients, so ENV conducted a survey to obtain a comprehensive overview of this topic. 32 countries were included. Many languages used English or Arabic term for cancer.

When advising cancer patients on their therapeutic course, "radiotherapy" was the most challenging modality to communicate. Words such as GRILLLING, ROASTING, BURNING WITH FIRE or ELECTRICITY were used, instilling fear. The work highlights attention to a neglected area in patient communication as we expand cancer therapeutic access across the region.



<u>ENV Branch</u>


Cosmos is the international prospective cohort study of mobile phone use and health, with subcohorts in the

The brain tumour analyses have recently been published in *Environment International*. These analyses were conducted on about 270 thousand participants which had accrued 1.8 million person-years of observation.

ENV did not find associations between mobile phone usage and occurrence of glioma, meningioma or acoustic neuroma.

There was no indication of increased risk with mobile phone usage, but the results are statistically imprecise.


The Cosmos study addresses limitations of previous



ENV Branch

2 implementation research studies on the impact of the 4th edition of the European Code Against Cancer:

- The first is a mobile Health or mHealth feasibility study carried out in Spain:
 - It is a population-based intervention study to investigate the impact of periodic broad dissemination of cancer prevention messages from the European Code through an APP of the Ministry of Health that reaches 67% of the population of Andalusia, the largest community of Spain.
 - It was designed under the Conceptual Framework for Implementation Outcomes, and the outcomes measured were adoption, fidelity, appropriateness and acceptability of the intervention, where all outcomes were high except fidelity, probably partly due to the disruptions that the study suffered by the Covid-19 pandemic
- The second is a qualitative research study across the EU to investigate the perceptions towards the adoption of European Code in the general population
 - It is a multi-country study to explore perceived capability, opportunity, and motivation of the general population to adopt the cancer prevention recommendations of the European Code, and to identify the barriers and facilitators for the adoption
 - It is framed under the COM-B model of behaviour that is widely used to identify what needs to change for a behaviour change intervention to be effective
 - The protocol has been published, and the thematic content analysis is currently been finalized to present the outcomes of capability, opportunity and motivation.



ENV Branch

TESTIS Pro is an extension of the TESTIS project - a French nationwide case-control study including 454 cases and 670 controls. This study was conducted in close collaboration with Centre Léon Bérard and Lyon 1 University as well as clinicians and exposure assessment scientists.

The main occupational exposures of interest were pesticides, solvents, and heavy metals including welding fumes.

At present we have published 6 papers from this project funded by Fondation de France.

The main results so far are:


- Paternal occupational exposure to heavy metals or welding fumes was not associated with TGCT development in their sons
- Maternal exposure to fuels and petroleum-based solvents during the pregnancy in sons born in the 1970s (OR 2.74, 95% CI 1.11–6.76) increased the risk of TGCT, i.e. in sub analysis by birth year
- Occupational exposure to trichloroethylene, ketone esters and fuels & petroleum-based solvents was associated with TGCT

Preliminary results in preparation or recently submitted include:

Paternal occupational exposure to herbicides at birth was associated with risk of TGCT in their sons

- Exposure to high levels of pesticides was significantly associated to TGCT
- Occupational exposure to lead, iron, cadmium, chromium, nickel and welding fumes was associated with TGCT. Metals and solvents are highly correlated, so it is not possible to fully distinguish their effects in observational studies. The full references and papers are available from the Occupational Cancer Epidemiology

team (OCE) webpage (<u>https://www.iarc.who.int/teams-oce/</u>).




ENV Branch

Nasal use of smokeless tobacco (snuff) is practiced by some Black South African women but has been rarely studied in relation to cancer risk. The exposure habits in these women are of interest, as use often starts in middle age or later. ENV conducted case-control studies designed within the Johannesburg Cancer Study. The prevalence of ever snuff use exceeded 30% in some tribes and displayed strong social gradients.

Increased cancer risks were found for:

- Cervical Cancer
- Cancer of the eye
- Vulval Cancer in current non-smoking snuff users


Further studies of snuff use in South African women are needed, especially associated with suggested genital exposure routes.



<u>EGM Branch</u>

Endemic Burkitt lymphoma and Leukaemia are the most prevalent childhood cancers in sub-Saharan Africa. However, their specific risk factors and molecular profiles are less studied in comparison to paediatric cancers from other regions in the world.

Therefore, EGM in partnership with ENV and researchers from Ghent University (Belgium) and Princess Maxima Centre (Netherlands) established collaborations with local partners from different countries of sub-Saharan Africa to collect biological samples from children at early life or at diagnosis. Those samples will be subjected to multi-omics, multi-infections and metabolomics analyses, which will allow to further identify risk factors, understand the mechanisms of development of these cancers and identify biomarkers of exposures, cancer risks and outcomes. Altogether this will set the basis for prevention studies and actions.




<u>EGM Branch</u>

Scientists from EGM and partner institutions have identified molecular markers in blood samples from newborn babies that may indicate a greater risk of developing leukaemia, the most common cancer type that affects children. These markers were also present in cancerous tissues from patients with leukaemia, and they served as indicators of patient survival. The findings were published in the journal *Molecular Cancer*.


The scientists searched for epigenome (DNA methylation) markers in surrogate (blood) and cancerous tissues across the development span of paediatric leukaemia, including at birth, diagnosis, remission, and recurrence. This study uncovered epigenetic precursors of leukaemia that could be detected at birth, before children develop the disease. In the absence of changes in the DNA code, the methylation levels of specific areas of DNA were differently modified in the blood of children who went on to develop paediatric leukaemia compared with those who did not. These epigenetic marks remained detectable in cancerous tissues collected at diagnosis, and hypermethylation was associated with significantly worse patient survival. The findings were reproducible with different technologies, in three continents, and in two ethnicities.

These results provide a proof of concept for the detection at birth of epigenetic alterations that predispose to paediatric leukaemia and affect the course of the disease in patients. Unlike genetic defects, epigenetic modifications are potentially reversible, and they can offer actionable targets for personalized therapy. These findings also hold promise for early detection of paediatric leukaemia, especially given that blood-based biomarkers are easy to measure and amenable to population screening.




<u>EGM Branch</u>

A 2024 Nature Medicine article by Basu et al. (EPR Branch) reported lower treatment success rates for cervical lesions in women living with HIV (WLHV) compared to HIV-negative women. As shown in this slide, analysis of the vaginal microbiome revealed that successful treatment correlated with an increase in Lactobacillus and a decrease in pathogenic bacteria over time. These findings suggest that Lactobacillus-dominant profiles could serve as predictive biomarkers for favourable cervical lesion treatment outcomes in HIV-positive patients.



<u>EGM Branch</u>

EGM and partners conduct an NIH/NIAAA-funded study on the role of ethanol and acetaldehyde in oral carcinogenesis. A broad, multisystem approach looks at the DNA damage in vivo and in vitro. The new mechanistic results obtained by IARC EGM show that mutational signature SBS17 forms in ethanol and acetaldehyde exposed rat tumors of the head area; and 2) acetaldehyde treatment induces DNA adducts and, 3) importantly, increases the genome-wide mutation burden in human non-cancer oral cells, suggesting specific modes of action for the carcinogenicity of ethanol or acetaldehyde.



<u>EGM Branch</u>

The causal roles of most of the specific chemical components present in tobacco in human cancer development are not clear. Therefore, the EGM Branch characterized the mutational signatures and underlying DNA damage of tobacco-specific nitrosamines in experimental models. The identified signature was then computationally screen for in almost 3000 cancer genomes from 37 tumor types. This provided the first evidence for the presence of a mutational signature of tobaccospecific nitrosamines, the POB signature, in tobacco-associated human cancers. The signature is predominantly found in certain hematological malignancies and other cancer types with no or little contribution of other smoking signatures.

Moreover, the study provides new insights into the contribution of tobacco nitrosamines to cancers in organs distinct from those under direct exposure, and it may have considerable implications for understanding the DNA damaging effects of electronic cigarettes, which also contain nicotine-derived nitrosamines.


Efficacy of single dose of HPV vaccine 15 years post-vaccination:				
outcomes from a cohort study in India				
 A cohort of females vaccinated at 10-18 years of age in 2009–2010 is being followed up for immunogenicity, efficacy against persistent infection and CIN 2/3 end points over last 15 years 	Study Group	Women assessed (N)	Persistent HPV 16/18 infection N (%; 95% Cl)	Persistent HPV 31/33/45 infection N (%; 95% Cl)
 The cohort includes recipients of a single dose (N=4949); 2-doses (N=4980) & 3-doses (N=4348) of Gardasil 	Unvaccinated	1,273	35 (2.7; 1.9-3.8)	17 (1.3; 0.8-2.1)
• An unvaccinated age-matched cohort was recruited post- hoc (<i>N=5172</i>)	All vaccinated	9,708	12 (0.1; 0.1-0.2)	54 (0.6; 0.4-0.7)
 Median follow up of 12 years demonstrate proportion of single dose recipients getting persistent HPV 16/18 infection is extremenly low (0.1%; 95% CI: 0.0-0.3) 	1-dose	3,022	4 (0.1; 0.0-0.3)	17 (0.6; 0.3-0.9)
 Vaccine efficacy against persistent HPV 16/18 infection was 92.0% (95% CI: 87-95)- same as 2 or 3 doses 	3-dose	2,172	2 (0.1; 0.0-0.3)	16 (0.7; 0.4-1.2)
 No case of HPV 16/18 related CIN 2/3 was detected in vaccinated women against 8 cases in the unvaccinated 	2-dose (D 1 & 180+)	2,311	2 (0.1; 0.0-0.3)	18 (0.8; 0.5-1.2)
	<u> </u>	N	1alvi et al. Natl Cance	er Inst Monogr. 2024.
Director's Report - SC/61 st Session 12	2–14 February 2025			36

EPR Branch

Scientists from EPR and partner institutions have demonstrated that the protection offered by a single dose of quadrivalent vaccine against persistent infection with human papillomavirus (HPV) types 16 and 18 – the HPV types responsible for nearly 80% of cervical cancers in low- and middle-income countries – is as high as that offered by two doses or three doses of the vaccine even **15 years** after the first dose of the vaccine was administered. The new report is part of a special issue of the *Journal of the National Cancer Institute Monographs*, published to coincide with the 36th International Papillomavirus Conference (IPVC), which took place in Edinburgh, United Kingdom, on 12–15 November 2024.

The research team is conducting **long-term follow-up** of a cohort of about 17 000 female participants in India who received three or two doses or a single dose of the quadrivalent HPV vaccine at age 10–18 years in 2009–2010. The vaccine efficacy of a single dose against persistent infection with HPV16 and 18 was found to be 92.0%, which was not significantly different from the efficacy of two doses or three doses of the vaccine. No high-grade cervical precancer associated with HPV16 and 18 was detected among vaccinated participants.

This study demonstrates the high efficacy of a single dose, as well as how vaccination will reduce HPV positivity rates and requirements for colposcopy within cervical screening programmes in real-life settings. The durable protection offered by a single dose 15 years after vaccination and the cost savings associated with lower HPV positivity rates and lower requirements for colposcopy and treatment as the vaccinated women undergo screening will support the decision of the 58 countries that already use a single dose in their HPV vaccination programmes and encourage other countries to do so.



<u>EPR Branch</u>

Rwanda was the first African country to implement national human papillomavirus (HPV) vaccination (against types HPV6, 11, 16, and 18). In 2011, a school-based catch-up programme was initiated to vaccinate girls aged younger than 15 years, but it also reached older girls in schools. The study aimed to estimate the effect of HPV vaccination on HPV prevalence in Rwanda and on future cervical cancer incidence, based on empirical data collected in a series of cross-sectional surveys in the general population.


Cross-sectional surveys were done between July, 2013, and April, 2014 (baseline), and between March, 2019, and December, 2020 (repeat), in sexually active women aged 17–29 years at health centres in the Nyarugenge District of Kigali, Rwanda. HPV prevalence was assessed in cervical cell samples. Adjusted overall, total, and indirect (herd immunity) vaccine effectiveness was computed as the

In Rwanda, the prevalence of vaccine-targeted HPV types has been significantly decreased by the HPV vaccine programme, most notably in women who were attending school during the catch-up programme in 2011. HPV vaccine coverage and population-level impact is expected to increase in future cohorts who are eligible for routine HPV vaccination at age 12 years.

Based on our findings, Rwandan public health authorities can reinforce their political and financial commitment towards cervical cancer elimination, improve vaccination coverage, and design adapted cervical cancer screening strategies. Public health authorities in other countries in sub-


Saharan Africa and elsewhere can learn from the Rwandan example, both in terms of implementing HPV vaccination and of monitoring its impact on HPV prevalence and cervical cancer burden.

The researchers found that improving the coverage of the current vaccination programme by reallocating resources could help to attain cervical cancer elimination in India and across all states of Brazil, but not in Rwanda unless the nonavalent vaccine is introduced.



<u>EPR Branch</u>


- IARC plays a leading role in the European initiatives for gastric cancer prevention.
- EUROHELICAN assesses the implementation aspects of the population-based H. pylori screen-and-treat programs for gastric cancer prevention in Europe. As part of the EUROHELICAN project, IARC has convened a Working Group of 32 experts from 21 countries to provide practical guidance on the implementation of the strategy.
- TOGAS, the largest project with 21 consortium members, will complement the EUROHELICAN project by providing, for the first time, essential information on both primary and secondary preventive strategies for gastric cancer in Europe.
- This knowledge and experience will be integrated into the new European Commission Initiative on Gastric Cancer which aims to develop the European guidelines and quality assurance schemes for gastric cancer prevention and care in Europe.



EPR Branch

In low- and middle-income countries (LMICs), access to immunohistochemistry (IHC) diagnostics for accurate breast cancer classification—which is critical for determining appropriate treatment and improving survival rates—is limited and often prohibitively expensive. This study, initiated in India and now being expanded to Uganda, aims to address these challenges by offering rapid and cost-effective breast cancer classification using a molecular assay (STRAT4).

The data presented in the table are derived from the project conducted in India. The project in Uganda has recently started.




<u>EPR Branch</u>


Scientists from EPR, in collaboration with engineers from NSV Incorporated (USA), have developed a revolutionary new artificial intelligence (AI) tool that can accurately detect cervical precancers and cancers in images of the cervix taken during appointments for cervical cancer screening. This innovative system will contribute to greater equity in global health because it has been designed specifically for use in low-resource settings, in contrast to many other AI and digital health solutions.

To train and validate the system's algorithm, IARC researchers used cervical images collected from nearly 1800 women who screened positive for human papillomavirus (HPV) and had a histopathology diagnosis, including some women living with HIV. The system was then evaluated independently using a different set of images that had not been seen by the algorithm during its training or internal validation. The system performed better than both Pap smear cytology and visual inspection with acetic acid (VIA), the tests currently recommended by the World Health Organization (WHO) to triage women who screen positive for HPV.


The IARC-developed system also offers significant advantages for use in low- and middle-income settings because it does not require an Internet connection to interpret the images, and it is battery-powered.



The following slides present some scientific highlights for **Pillar 4 – knowledge mobilization**, that includes the **Evidence Synthesis and Classification (ESC) Branch** and the **Learning and Capacity Building (LCB) Branch**.



ESC Branch – Monographs Programme




ESC Branch – Monographs Programme

	2024 Highlights of the IARC Handbooks Programme		
• • • •	 Handbook Vol. 20A " Reduction or Cessation of Alcoholic Beverage Consumption": May 2023 Gapstur et al. (2023) "The IARC Perspective on Alcohol Reduction or Cessation and Cancer Risk". NEJM Q&A and Infographics posted on the Handbooks and IARC websites Full Volume published online and in print Handbook Vol. 20B "Alcohol Policies": October 2024 Collaboration with and partially funded by WHO EURO Special Report submitted to NEJM (December 2024) Handbook Vol. 21 "Lung Cancer Screening": April 2026 Partially funded by UICC Meeting has been announced on IARC and Handbooks websites WCRF project – Early life adiposity and breast cancer incidence Integration of mechanistic evidence in the overall evaluation by the WCRF CUP global panel (Nov. 2024) Population Attributable Fraction (PAF) Estimation of the global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut use (IARC group 1 carcinogens); in collaboration with the Cancer Surveillance Branch Evidence Gap Map (EGM) project Evidence and gap map (EGM) on oral cancer prevention, based on the systematic reviews from HB 19; in collaboration with the University of New Castle (UK) and the University of Campinas (Brazil) Four book reviews of Handbook Vol. 19, published in medical journals in Brazil, India, Poland, Saudi Arabia 	Anton	
	Director's Report - SC/61 st Session 12-14 February 2025	44	


ESC Branch – Handbooks Programme

WHO Classification of Tumours Programme				
WCT 5 th edition				
1. Head and Neck Tumours Parts A and B. WHO Classification of Tumours, 5 th Edition, Volume 9. 2024. ISBN-13: 978-92-832-4514-8.				
2. Haematolymphoid Tumours Parts A and B. WHO Classification of Tumours, 5 th Edition, Volume 11. 2024. ISBN-13: 978-92-832-4520-9.	VEC instructions of feature 1 and the set of			
Published studies 2024				
1. WHO Classification of Tumours: moving towards the sixth edition Histopathology. 2024 Sep 18. doi: 10.1111/his.15325. PMID: 39293942.				
 Moving Forward on Tumour Pathology Research Reporting: A Guide for Pathologists From the World Health Organization Classification of Tumours Living Evidence Gap Map by Tumour Type Group. Mod Pathol 2024 Jul;37(7):100515. doi: 10.1016/j.modpat.2024.100515. PMID 38763419. 	F Put A Put			
 A New Hierarchy of Research Evidence for Tumour Pathology: A Delph Study to Define Levels of Evidence in Tumour Pathology. Mod Pathol. 2024 Jan;37(1):100357. doi: 10.1016/j.modpat.2023.100357. PMID: 37866639. 				
 Exploratory evidence maps for the WHO Classification of Tumours 5th edition for lung and thymus tumours. Virchows Arch. 2024 Nov;485(5):869-878. doi: 10.1007/s00428-024-03886-6. PMID: 39448408. 				
Director's Report - SC/61st Session 12-14 February 2025	45			

ESC Branch WHO Classification of Tumours (WCT Programme)



ESC Branch WHO Classification of Tumours (WCT Programme)



The Research Training and Fellowship Programme offers researchers at different levels of their career opportunities to get trained at IARC through their participation in collaborative research projects.

Those Early Career and Visiting Scientists (ECVS) are supported either by project funds from IARC Groups or by IARC Fellowships.

Over 220 ECVSs were hosted at IARC in 2024, among which over 90 postdoctoral scientists. This is an increase compared to previous years and is certainly related to the success of scientific branches to increasingly attract external funding.

We periodically carry out outcomes surveys to document the impact of the programme and to identify areas of improvements. The latest survey was conducted early 2024 targeting over 140 doctoral students and postdoctoral scientists who benefited from the Programme between 2019 to early 2024.

Results are consistent with data collected in the 5 previous survey carried out since 2012: the IARC Research Training and Fellowship Programme is a fantastic opportunity for early career scientists to assemble complementary skills in preparation for a high-level scientific career.




The next call for IARC Fellowships has been postponed to March 2025, as its scope may vary according to the outcome of a grant application to EU.

We are currently working with the Mark Foundation for Cancer Research to renew its commitment to the programme, with one fellowship supported.

A new partnership with the Instituto de Salud Carlos III in Spain will allow us to include in the call 2 dedicated fellowships targeting early career scientists from Spain, with a 2 year return grant in the country.

Finally, Wallonie-Bruxelles International will allocate, through their current call, 2 postdoctoral fellowships of 2 years each at IARC. These will target students/scientists from Wallonie's universities (Belgium or of different nationality).



The Summer School, held biennially, currently consists of two modules:

- Introduction to cancer epidemiology: This module focuses on the practical application of epidemiological principles to cancer control, the search for cancer causes, and the evaluation of control programmes.

- Implementing cancer prevention and early detection: This module covers cancer control strategies, risk factors, prevention approaches, and the principles of screening programmes.

The call for the 2025 edition was open until January.

The IARC Learning Space on the WHO Academy Learning Experience System			
e World Health Departantion Deer	no Q Search	Optimization Discovery Courses Optimization Login Auguston St. EH	
WHO Academy BR Home	Discovery		
Q Discovery	Top quality learning spaces	International Agency for Research on Cancer	
ତ୍ର୍ My Learning ୍ ୍	Vordi Health Creanization Creanization European Region	Anot Course g up URC-ESMO Learning and Capacit	
Settings	Top courses	Joint Action on the New EU Can Evidence-based professional det	
() Feedback	LARC Challenges and Opportunities	Mounter to the statistication (transmit year) IARC Cancer Screening In Five acc) Automatication (transmit year) Mark to the statistication (transmit year) Mark to the station (transmit yea	
		National Projects	
	Self-paced Ex EN	If paced Image: Control of Self paced Image: Control of Self paced Image: Control of Self paced https://web-staging.lxp.academy.who.int/partners/IARC	
Director's Report	- SC/61st Session	12–14 February 2025	50

The IARC Learning and Capacity Building Branch and the WHO Academy team in charge of developing the Academy's Learning Experience Platform (LXP) have been collaborating closely since October 2023. IARC has provided extensive inputs on functionalities that are instrumental to the implementation of IARC courses. The WHO Academy team has successfully implemented most of these functionalities in the LXP.


A dedicate learning space was designed for IARC to be able to autonomously create and manage its own courses. From the user's perspective, the IARC learning space is clearly visible and accessible from the LXP "course discovery" page. Users can easily identify the IARC courses in the list of all courses displayed.

CLICK

The IARC Learning Space includes Initiatives, which allow us to compile on a single page the resources that have been developed in the frame of a specific project, and to give the necessary acknowledgement and visibility to project's contributor(s).

(Note: to be updated around beg-January for actual presentation)

As of today, IARC has migrated 22 courses from its former platform to the WHO Academy's learning experience system. The migration of the IARC Learning users is planned for the beginning of 2025.



LCB was involved in most learning activities led by scientific Branches in different ways: advice or support on learning needs assessment, instructional design, organization, development of online evaluation surveys and/or through the development of online spaces on the learning infrastructure.

LCB has also contributed to Branches' initiatives where there is a training component embedded within a broader project and has collaborated with scientific Branches for the development of proposals and running of projects.

Examples of such joint projects include the following:

- The Human Exposome Assessment Platform (HEAP). LCB and NME/LSB Branches are leading the Education and Dissemination work package.
- Comprehensive Cancer Infrastructures for Europe (CCI4EU). Together with the EPR and CSU Branches, LCB is co-leading IARC's contribution, namely: define maturity criteria for comprehensive cancer infrastructures, specifically as far as screening and population-based cancer registration are concerned; carry out tailored interventions in selected countries; develop an online resource centre gathering

capacity building interventions. LCB is specifically leading the last activity.

• The HPV Vaccine Effectiveness Coordination Center (CHRONOS). This five-year project funded by Bill & Melinda Gates Foundation that started in October 2023, under the coordination of the IARC EPR Branch. LCB is leading the development and implementation of the training strategy of the project.



The following slides report some highlights from the meeting of the **66th Session of the Governing Council** held in Lyon on 15-16 May 2024.




Admission of two new Participating States The Kingdom of Saudi Arabia (28th) and Egypt (29th)



IARC welcomed the Kingdom of Saudi Arabia (KSA) and Egypt as its 28th and 29th Participating State respectively, highlighting KSA and Egypt's dedication to advancing cancer research and prevention efforts.

<section-header><section-header><section-header><text><list-item><list-item><complex-block><complex-block>



Director's Report - SC/61st Session

12–14 February 2025

Evaluability assessment of the IARC Medium-Term Strategy (MTS) 2021–2025 and establishment of a Working Group

The Governing Council,

- □ APPROVED the proposed workplan and process for the evaluation of the MTS 2021–2025;
- □ ESTABLISHED a Working Group for the purpose of preparing the MTS 2021–2025 evaluation, composed of **two members of the Scientific Council** (Dr Pål Romundstad and Dr Luis Felipe Ribeiro Pinto), **two members of the Governing Council** and a **representative from the World Health Organization**;
- NOMINATED two Governing Council representatives from France and Spain, to be part of the Working Group; and
- REQUESTED the Director to submit the Evaluation Report of the IARC Medium-Term Strategy for 2021–2025 for review by the Scientific Council at its 61st Session in February 2025 and approval by the Governing Council at its 67th Session in May 2025.

Director's Report - SC/61st Session

12–14 February 2025

Preparation of the IARC Medium-Term Strategy (MTS) 2026–2030 and establishment of a Working Group

The Governing Council,

□ APPROVED the proposed timeline for the preparation of the MTS 2026–2030;

- ESTABLISHED a Working Group for the purpose of preparing the new IARC MTS for 2026–2030, composed of two members of the Scientific Council (Dr Mohamed Berraho and Dr Satish Gopal), three members of the Governing Council and a representative from the World Health Organization;
- □ NOMINATED the three respective Governing Council representatives from **Brazil, Egypt** and Saudi Arabia, to be part of the Working Group; and
- □ REQUESTED the Director to submit the IARC Medium-Term Strategy 2026–2030 for review by the Scientific Council at its **62nd Session in February 2026** and adoption by the Governing Council at its **68th Session in May 2026**.

Director's Report - SC/61st Session

12–14 February 2025



IARC'S COVID-19 and cancer initiative

The Governing Council,

- □ THANKED the Secretariat for the update on this initiative, noting the new name as now being "IARC-IRCC: Initiative for Resilience in Cancer Control";
- □ THANKED Australia and the United Kingdom of Great Britain and Northern Ireland for their voluntary contributions to support funding for this initiative; and
- □ REQUESTED **regular updates** to the Governing Council by the IARC Secretariat on progress throughout the term of the initiative.

Director's Report - SC/61st Session

12–14 February 2025




Governing Council Working Group to examine IARC infrastructure projects

The Governing Council,

- NOTED that the work of the Working Group to examine IARC infrastructure projects has been duly accomplished and that, with the move to the Nouveau Centre building, it is no longer required;
- DECIDED to **discontinue the Working Group** to examine IARC infrastructure projects; and
- □ THANKED the members of the Working Group, in particular Canada, France, Germany and Switzerland, for their work and longstanding support.

Director's Report - SC/61st Session

12–14 February 2025



Director's Report - SC/61st Session

12-14 February 2025

Acceptance of grants, contracts and donations		
The Governing Council,		
□ CONFIRMED the provisional approval given by the Governing Council Chair for the following projects:		
 a. European Cervical Screening Quality Assurance Update [European Commission European Health And Digital Executive Agency: EU4H, in an amount of €1 080 000.00 for 36 months] 		
b. HPV Vaccine Effectiveness Coordination Center [Bill & Melinda Gates Foundation, in an amount of €3 213 228.93 for 60 months];		
c. Cancer in Children – Epidemiology, Registration, Omics [Ministry of Health, Welfare and Sport of Netherlands, in an amount of €1 535 055 for 36 months]		
COMMENDED the staff on its success in winning competitive research grants.		
 □ NOTED that the Director allocated €80 000 in 2023 from the Special Account for Undesignated Contributions for the Postdoctoral Fellowship programme. Director's Report - SC/61st Session 12-14 February 2025 		

IARC 60th Anniversary

The Governing Council,

□ NOTED with great interest the proposal for celebrating the 60th anniversary of IARC; and

□ ENDORSED the **one-year campaign** culminating in the Scientific Conference to celebrate the 60th anniversary.

Director's Report - SC/61st Session

12–14 February 2025


Appointment of new mem The Governing Council,	bers of the Scientific Council
Professor Adam Grant Elshaug, Australia Professor Eric Van Cutsem, Belgium Professor Hesham Elghazaly, Egypt Professor Tatsuhiro Shibata, Japan Dr Ali Saeed Al-Zahrani, Kingdom of Saudi Arabia Dr María José Sánchez Pérez, Spain Professor Richard Sullivan, United Kingdom	to serve for four years on the Scientific Council
(Belgium), Manami Inoue (Japan), Ferrán Catalá (S valuable work in the Scientific Council.	ic Council, Drs Louisa Gordon (Australia), Marc Arbyn pain) and Kalipso Chalkidou (United Kingdom) for their

Date of the sixty-seventh se	ession of the Governing Council	
 The Governing Council, DECIDED to hold its next regular session in Lyon, France, on 6–8 May 2025, within the two weeks preceding the opening of the World Health Assembly in 2025. 		
Director's Report - SC/61st Session 12–14 F	ebruary 2025 67	



The following slides report some highlights from the **60th session of the Scientific Council** held at IARC on 7-9 February 2024.







Discussion on the evaluability assessment of the IARC Medium-Term Strategy (MTS) 2021–2025 and its Working Group membership
 A dedicated Working Group will review the draft report on the evaluation of the MTS 2021–2025 and provide its recommendations to the Scientific Council in February 2025 and to the Governing Council in May 2025.
 The Scientific Council nominated Pål Richard Romundstad and Luis Felipe Ribeiro Pinto to be part of the Working Group.

Director's Report - SC/61st Session

12–14 February 2025



Director's Report - SC/61st Session


12–14 February 2025




Director's Report - SC/61st Session

12–14 February 2025

Excellent feedback! The Scientific Council congratulated the Director and her staff on the flash talks:
Excellent overview from Branch Heads/high quality videos
Relevant selection of presentations
Excellent to outstanding presentations from scientists and scientific staff/high scientific quality/Homogenised presentations
Diversity of backgrounds highly appreciated
Alignment with MTS very high
Good collaboration across Branches/high collaboration with external partners
Catalyst/unique role of IARC in LMICs demonstrated
High to very high anticipated public health impact/support to WHO Global Initiatives
Very cooperative atmosphere
Suggestion for next year flash-talks session (SC/61, February 2025):
Given that SC/61 will be held remotely, the Secretariat suggests that flash-talks be held online, early December 2024, as was done in the past for sessions of the Scientific Council held fully remotely:
Overview of Branch activities by Branch Heads (5-min video)
5 flash talks per Branch








Update on the COVID-19 and cancer initiative		
 The Scientific Council congratulated IARC on its progress to date in this area. Comments/recommendations on: ✓ Rebranding Initiative ✓ Dissemination Strategy ✓ Attention to Essential Service Interruption ✓ Positive COVID Findings Integration 		
Director's Report - SC/61 st Session 12-14 February 2025	79	

<section-header><section-header> Dissemination and communication strategy "celebrating 60 years of LAC's research" Arc is embarking on a new journey by creating a year-long campaign to celebrate its 60th anniversary that will cummate in the organization of a Grand Scientific Conference in May 2026. Comments/recommendations on: Angage youth. Dissemination Beyond Scientific Community. Pisemination Beyond Scientific Community. Pisemination Beyond Scientific Community. Aromotional Campaigns and Ambassadors. Distinguish from Governments. Anever of Storytelling. Increase Visibility. Bustainability and Goal Definition.



Election of Chair and Vice-chair for the 61st session of the Scientific Council – date of next session-

Dr Luis Felipe Ribeiro Pinto was elected Chairperson.

Dr Sirpa Heinävaara was elected Vice-Chairperson.

The 61st session of the Scientific Council will take place on:

Wednesday 12, Thursday 13 and Friday 14 February 2025

The meeting will be held remotely.

Director's Report - SC/61st Session

12-14 February 2025

